P. Pautier

发表

Cutaneous side-effects of kinase inhibitors and blocking antibodies.

Alain Spatz, Caroline Robert, J. Soria, 2005, The Lancet. Oncology.

Results of conservative management of epithelial malignant and borderline ovarian tumours.

R. Rouzier, D. Atallah, P. Morice, 2003, Human reproduction update.

S. Delaloge, P. Duvillard, P. Pautier, 2002, International Journal of Gynecologic Cancer.

Safety of bevacizumab in clinical practice for recurrent ovarian cancer: A retrospective cohort study.

I. Ray-Coquard, F. Goldwasser, O. Trédan, 2016, Oncology letters.

Outcomes After Combined Therapy Including Surgical Resection in Patients with Epithelial Ovarian Cancer Recurrence(s) Exclusively in Lymph Nodes

C. Haie-meder, P. Morice, C. Uzan, 2004, International Journal of Gynecologic Cancer.

[Systemic therapy for advanced endometrial cancer].

P. Pautier, F. Pommeret, 2017, Bulletin du cancer.

Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol

P. Viens, J. Gligorov, F. Selle, 2006, Bone Marrow Transplantation.

A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies.

M. Ducreux, E. Raymond, E. Baudin, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Surgical procedures and morbidities of diaphragmatic surgery in patients undergoing initial or interval debulking surgery for advanced-stage ovarian cancer.

C. Haie-meder, P. Morice, C. Uzan, 2010, Journal of the American College of Surgeons.

[Adjuvant radiotherapy in patients with endometrial cancers].

C. Haie-meder, P. Morice, P. Pautier, 2011, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[Adjuvant therapy and role of radiation therapy in advanced endometrial cancers].

C. Haie-meder, P. Morice, C. Touboul, 2008, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group.

C. Haie-meder, F. Bertucci, B. Weber, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case‐control study with radiotherapy alone

C. Haie-meder, P. Morice, P. Kerbrat, 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)

A. Reuss, J. Ledermann, F. Marmé, 2020, International Journal of Gynecological Cancer.

[Rare ovarian tumours: therapeutic strategies in 2010, national website observatory for rare ovarian cancers and delineation of referent centers in France].

I. Treilleux, I. Ray-Coquard, P. Morice, 2010, Bulletin du cancer.

Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours

C. Genestie, A. Dunant, J. Scoazec, 2019, British Journal of Cancer.

Sentinel Lymph Node in Endometrial Cancer: A Review

C. Haie-meder, P. Morice, C. Uzan, 2013, Current Oncology Reports.

The obese endometrial cancer patient : how dowe effectively improve morbidity and mortality in this patient population ?

A. Leary, N. Colombo, P. Morice, 2016 .

Breast Cancer Patients’ Experience and Wishes Regarding Communication on Sexual Health - The BEROSE Study

B. Pistilli, S. Delaloge, F. Scotté, 2021 .

Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial

A. Fourcade, É. Minvielle, D. Planchard, 2022, Nature Medicine.

Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies.

E. Raymond, J. Soria, S. Faivre, 2008, European journal of cancer.

Novel membrane-based targets - Therapeutic potential in gynecological cancers.

A. Leary, M. Gizzi, P. Pautier, 2015, Critical reviews in oncology/hematology.

Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers.

C. Genestie, R. Rouzier, F. Guyon, 2019, European journal of cancer.

Exclusive radiotherapy for primary squamous cell carcinoma of the vagina.

C. Haie-meder, N. Sanfilippo, A. Gerbaulet, 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Results of Hysterectomy in Patients With Bulky Residual Disease at the End of Chemoradiotherapy for Stage IB2/II Cervical Carcinoma

C. Haie-meder, P. Morice, P. Duvillard, 2005, Annals of Surgical Oncology.

Radiotherapy and radical surgery for treatment of patients with bulky stage IB and II cervical carcinoma.

C. Haie-meder, P. Morice, P. Duvillard, 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease

D. Planchard, O. Mir, M. Ducreux, 2022, Cancers.

Cystogastric transmural drainage for the treatment of symptomatic cystic metastases from ovarian carcinoma.

T. de Baère, A. Roche, M. Lewin, 1999, Journal of vascular and interventional radiology : JVIR.

Current Standards in the Management of Early and Locally Advanced Cervical Cancer: Update on the Benefit of Neoadjuvant/Adjuvant Strategies

C. Genestie, P. Morice, Yuedan Zhou, 2022, Cancers.

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Small Cell Cancers

D. Provencher, M. Friedlander, A. Fyles, 2014, International Journal of Gynecologic Cancer.

Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting.

H. Comber, J. Rashbass, I. Vergote, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer

G. Hall, V. Ostapenko, B. Melichar, 2017, International Journal of Gynecologic Cancer.

Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx®) in combination with topotecan in patients with advanced malignancies

E. Raymond, J. Armand, S. Faivre, 2006, Investigational New Drugs.

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.

C. Robert, B. Besse, O. Lambotte, 2019, The Lancet. Haematology.

Surgical Management for Prophylactic Oophorectomy in Women with an Inherited Risk of Ovarian Cancer

A. Chompret, P. Morice, S. Delaloge, 2001, Tumori.

Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study.

O. Trédan, F. Gernier, E. Kalbacher, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Response of ovarian carcinomas to gefitinib–carboplatin–paclitaxel combination is not associated with EGFR kinase domain somatic mutations

J. Soria, J. Bidart, L. Lacroix, 2006, International journal of cancer.

Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin

F. Amant, F. Duffaud, A. Mustea, 2015, Sarcoma.

Multimodal Treatment With Doxorubicin, Cisplatin, and Ifosfamide for the Treatment of Advanced or Metastatic Uterine Leiomyosarcoma: A Unicentric Experience

C. Haie-meder, C. Balleyguier, A. Leary, 2015, International Journal of Gynecologic Cancer.

Gynecologic Cancer InterGroup (GCIG) Consensus Review: Uterine and Ovarian Leiomyosarcomas

Jae-Weon Kim, I. Ray-Coquard, D. Gaffney, 2014, International Journal of Gynecologic Cancer.

Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma

C. Haie-meder, C. Genestie, P. Morice, 2000, Cancer.

Results of oxaliplatin-based hyperthermic intraperitoneal chemotherapy in recurrent ovarian granulosa cell tumors.

P. Morice, C. Uzan, S. Gouy, 2013, European journal of obstetrics, gynecology, and reproductive biology.

Rare Ovarian Cancers

I. Ray-Coquard, P. Morice, J. Gligorov, 2009 .

The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study.

D. Berton, F. Guyon, N. Radosevic-Robin, 2020, Gynecologic oncology.

Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network

D. Berton, P. Colombo, I. Treilleux, 2022, Cancers.

ESGO-SIOPE guidelines for the management of adolescents and young adults with non-epithelial ovarian cancers.

C. Sessa, N. Concin, D. Orbach, 2020, The Lancet. Oncology.

Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before chemoradiotherapy in the era of positron emission tomography imaging.

C. Haie-meder, P. Morice, C. Uzan, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Para-Aortic Involvement and Interest of Para-Aortic Lymphadenectomy after Chemoradiation Therapy in Patients with Stage IB2 and II Cervical Carcinoma Radiologically Confined to the Pelvic Cavity

C. Haie-meder, P. Morice, C. Uzan, 2007, Annals of Surgical Oncology.

Prognostic factors in women treated for ovarian yolk sac tumour: a retrospective analysis of 84 cases.

C. Haie-meder, S. Culine, P. Morice, 2011, European journal of cancer.

Surgical Implications of Advanced Low-Grade Serous Ovarian Cancer: Analysis of the Database of the Tumeurs Malignes Rares Gynécologiques Network

I. Ray-Coquard, A. Bats, M. Le Frère-Belda, 2022, Cancers.

Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.

A. Reuss, I. Vergote, J. Sehouli, 2019, Gynecologic oncology.

Transitory Stoma at the Time of Complete Cytoreductive Surgery Affects Survival for Patients with Advanced-stage Ovarian Cancer.

Cyrus Chargari, C. Genestie, P. Morice, 2018, Anticancer research.

Correlation Between Macroscopic and Microscopic Diseases on Splenectomies Performed in the Surgical Management of Ovarian Cancer

C. Uzan, S. Gouy, P. Duvillard, 2010, International Journal of Gynecologic Cancer.

Patterns of care and outcome in elderly cervical cancer patients: a special focus on brachytherapy.

C. Haie-meder, N. Magné, E. Chajon, 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.

I. Treilleux, I. Ray-Coquard, V. Marcel, 2022, JAMA oncology.

Providing Patients with Locally Advanced Cervical Cancer Access to Brachytherapy: Experience from a Referral Network for Women Treated in Overseas France

V. Vinh-Hung, P. Morice, S. Gouy, 2022, Cancers.

Outcome of Patients With Incomplete Resection After Surgery for Stage IB2/II Cervical Carcinoma With Chemoradiation Therapy

C. Haie-meder, C. Balleyguier, P. Morice, 2010, International Journal of Gynecologic Cancer.

Accuracy of magnetic resonance imaging in predicting residual disease in patients treated for stage IB2/II cervical carcinoma with chemoradiation therapy

C. Haie-meder, C. Balleyguier, P. Morice, 2008, Cancer.

Detection of minimal levels of serum anti-Müllerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay.

J. Bidart, R. Rey, J. Picard, 2000, The Journal of clinical endocrinology and metabolism.

Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer

C. Genestie, J. Adam, A. Leary, 2018, Cancers.

Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond SMARCA4 Mutations: A Comprehensive Genomic Analysis

M. Rubin, O. Elemento, C. Genestie, 2015, Cells.

Alpha-fetoprotein production by a malignant mixed Müllerian tumor of the ovary.

P. Morice, P. Duvillard, P. Pautier, 2000, Gynecologic oncology.

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

F. Marmé, I. Vergote, S. Pignata, 2019, The New England journal of medicine.

Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study.

I. Ray-Coquard, A. Floquet, D. Berton‐Rigaud, 2019, Journal of Clinical Oncology.

Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

I. Ray-Coquard, N. Colombo, J. Prat, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Small Cell Carcinoma of the Ovary

A. Leary, A. Auguste, P. Pautier, 2017 .

Prophylactic surgery in patients with inherited risk of ovarian cancer.

P. Morice, S. Delaloge, P. Pautier, 2001, Gynecologic oncology.

Impact of epidural analgesia on survival in patients undergoing complete cytoreductive surgery for ovarian cancer.

P. Morice, C. Uzan, S. Gouy, 2012, Anticancer research.

The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type.

J. Trent, H. Cunliffe, A. Berchuck, 2016, Gynecologic oncology.

Hematologic recovery and survival of lymphoma patients after autologous stem-cell transplantation: comparison of bone marrow and peripheral blood progenitor cells.

H. Dombret, C. Gisselbrecht, D. Cazals, 1996, Leukemia & lymphoma.

Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.

P. Fasching, F. Marmé, I. Vergote, 2022, European journal of cancer.

Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.

F. Bertucci, A. Italiano, C. Balleyguier, 2022, The Lancet. Oncology.

Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape.

C. Genestie, A. Leary, P. Morice, 2020, Gynecologic oncology.

Fertility results and pregnancy outcomes after conservative treatment of cervical cancer: a systematic review of the literature.

Cyrus Chargari, P. Morice, S. Gouy, 2016, Fertility and sterility.

Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.

S. Novello, E. Raymond, J. Armand, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

355 Pembrolizumab and bevacizumab in platinum resistant epithelial ovarian cancer patients

C. Genestie, A. Paci, C. Balleyguier, 2021, Journal for ImmunoTherapy of Cancer.

Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type.

F. Mayer, P. Morice, P. Kerbrat, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[Systemic therapy for advanced endometrial cancer].

P. Pautier, C. Lhommé, Y. Tazi, 2012, Bulletin du cancer.

Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy.

D. Atallah, P. Morice, P. Duvillard, 2004, European journal of gynaecological oncology.

Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications.

R. Rouzier, D. Atallah, P. Morice, 2003, Journal of the American College of Surgeons.

Value and cost evaluation of routine follow-up for patients with clinical stage I/II endometrial cancer.

C. Haie-meder, P. Morice, P. Duvillard, 2001, European journal of cancer.

Endometrial disorders in patients with peritoneal serous papillary carcinoma.

P. Morice, P. Duvillard, P. Pautier, 2007, European journal of obstetrics, gynecology, and reproductive biology.

Lymph node spread in stage III or IV primary peritoneal serous papillary carcinoma.

P. Morice, P. Duvillard, G. Dubernard, 2005, Gynecologic oncology.

Prognosis of stage III or IV primary peritoneal serous papillary carcinoma.

P. Morice, C. Pomel, P. Duvillard, 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Lymphocele and ovarian cancer: risk factors and impact on survival.

P. Morice, C. Uzan, S. Gouy, 2012, The oncologist.

Histological response is not a prognostic factor after neoadjuvant chemotherapy in advanced-stage ovarian cancer with no residual disease.

P. Morice, C. Uzan, S. Gouy, 2009, European journal of obstetrics, gynecology, and reproductive biology.

FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.

A. Oza, M. Birrer, I. Vergote, 2018, Future oncology.

Use of first line trabectedin in advacned leiomyosarcoma: a review of clinical data and future perspectives

P. Pautier, 2016 .

Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.

S. Pignata, C. Sessa, I. Ray-Coquard, 2018 .

Ovarian metastasis on transposed ovary in patients treated for squamous cell carcinoma of the uterine cervix: report of two cases and surgical implications.

C. Haie-meder, P. Morice, P. Pautier, 2001, Gynecologic oncology.

Prognostic value of lymphovascular space invasion determined with hematoxylin-eosin staining in early stage cervical carcinoma: results of a multivariate analysis.

C. Haie-meder, D. Atallah, P. Morice, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized, open-label, phase II study assessing the efficacy and the safety of bevacizumab in neoadjuvant therapy in patients with FIGO stage IIIc/IV ovarian, tubal, or peritoneal adenocarcinoma, initially unresectable.

R. Rouzier, F. Guyon, P. Colombo, 2014 .

Rosia: A Single-Arm Study in More Than 1000 Patients (PTS) Receiving Front-Line Bevacizumab (BEV) + Chemotherapy (CT) for Ovarian Cancer (OC)

A. Oza, N. Colombo, F. Selle, 2012 .

Value of routine follow-up procedures for patients with stage I/II cervical cancer treated with combined surgery-radiation therapy.

C. Haie-meder, D. Atallah, P. Morice, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Surgical procedure in patients with ovarian cancer diagnosed at the time of prophylactic oophorectomy. Analysis of two cases, literature review and surgical implications.

A. Chompret, P. Morice, S. Delaloge, 2004, European journal of obstetrics, gynecology, and reproductive biology.

A new score based on biomarker values to predict the prognosis of locally advanced cervical cancer.

C. Genestie, A. Leary, P. Morice, 2020, Gynecologic oncology.

[Recent data in cervical cancer: Radiation oncologist's perspective].

C. Haie-meder, S. Gouy, C. Chargari, 2018, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Prognostic value of initial surgical procedure for patients with uterine sarcoma: analysis of 123 patients.

C. Haie-meder, C. Genestie, D. Atallah, 2003, European journal of gynaecological oncology.

Primary yolk sac tumor of the endometrium: a case report and review of the literature.

A. Spatz, P. Duvillard, P. Pautier, 1998, Gynecologic oncology.

Prognosis and prognostic factors of the micropapillary pattern in patients treated for stage II and III serous borderline tumors of the ovary.

C. Haie-meder, P. Morice, C. Uzan, 2011, The oncologist.

Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants.

P. Morice, C. Uzan, S. Gouy, 2009, The oncologist.

Results After Conservative Treatment of Serous Borderline Tumors of the Ovary with a Micropapillary Pattern

P. Morice, C. Uzan, S. Gouy, 2008, Annals of Surgical Oncology.

Inhibin B is the major form of inhibin/activin family secreted by granulosa cell tumors.

F. Petraglia, J. Bidart, J. Sabourin, 1998, The Journal of clinical endocrinology and metabolism.

Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

I. Ray-Coquard, N. Colombo, J. Prat, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Characteristics and Prognosis of Stage I Ovarian Mucinous Tumors According to Expansile or Infiltrative Type.

C. Genestie, A. Leary, M. Devouassoux‐Shisheboran, 2018, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Neuroendocrine small cell carcinoma of the uterine cervix: what disease? What treatment? Report of ten cases and a review of the literature.

C. Haie-meder, S. Delaloge, P. Kerbrat, 2000, Clinical oncology (Royal College of Radiologists (Great Britain)).

Malignant blue nevus of the vulva with late ovarian metastasis.

A. Spatz, P. Duvillard, P. Pautier, 1998, The American Journal of dermatopathology.

Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature.

T. Molina, H. Dombret, A. Delmer, 1999, Leukemia & lymphoma.

Malignant effusions and immunogenic tumour-derived exosomes

L. Zitvogel, F. André, G. Raposo, 2002, The Lancet.

Improving treatment results with reference centres for rare cancers: where do we stand?

J. Blay, J. Coindre, A. Le Cesne, 2017, European journal of cancer.

Cyclophosphamide induces differentiation of Th17 cells in cancer patients.

L. Zitvogel, N. Chaput, J. Soria, 2011, Cancer research.

Analysis of Systemic Inflammatory Factors and Survival Outcomes in Endometrial Cancer Patients Staged I-III FIGO and Treated with Postoperative External Radiotherapy

C. Haie-meder, C. Genestie, E. Deutsch, 2020, Journal of clinical medicine.

Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial

F. Marmé, A. Gadducci, J. Rau, 2016, International Journal of Gynecologic Cancer.

Small-Cell Carcinoma of the Ovary, Hypercalcemic Type–Genetics, New Treatment Targets, and Current Management Guidelines

J. Trent, W. Foulkes, A. Oza, 2020, Clinical Cancer Research.

Small Cell Carcinoma of the Ovary, Hypercalcaemic Type – genetics, new treatment targets and current management guidelines

J. Trent, W. Foulkes, A. Oza, 2020 .

Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. The Groupe d'Etude des Lymphomes de l'Adulte.

B. Coiffier, H. Tilly, É. Lepage, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Peripheral neuropathy in association with an ovarian dysgerminoma.

P. Duvillard, T. Dubard, O. Rixe, 2003, Gynecologic oncology.

Necrotic cutaneous lesions induced by hypereosinophilic syndrome secondary to a T-cell lymphoma.

V. Meignin, A. Janin, S. Aractingi, 2002, Journal of the American Academy of Dermatology.

Surgery for recurrent ovarian cancer: expert point of view

B. Asselain, G. Ferron, F. Lécuru, 2021, Gynecology and Pelvic Medicine.

Standards, Options et Recommandations 2006. Prise en charge des patients adultes atteints de sarcome des tissus mous, de sarcome utérin ou de tumeur stromale gastro-intestinale

S. Bonvalot, P. Morice, F. Bonichon, 2007, Oncologie.

S. Delaloge, P. Duvillard, P. Pautier, 2003, International Journal of Gynecologic Cancer.

Letter to the Editor and reply

S. Delaloge, P. Duvillard, W. McCluggage, 2003 .

Letter to the Editor

S. Delaloge, P. Duvillard, P. Pautier, 2003, International Journal of Gynecologic Cancer.

Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database

R. Rouzier, I. Ray-Coquard, A. Floquet, 2022, Cancers.

Bevacizumab Does Not Reduce the Lymphocele Rate in Advanced Ovarian Cancer After Complete Cytoreductive Surgery.

C. Genestie, A. Leary, P. Morice, 2018, Anticancer research.

Laparoscopic ovarian transposition for pelvic malignancies: indications and functional outcomes.

C. Haie-meder, P. Morice, P. Duvillard, 1998, Fertility and sterility.

Fertility results after ovarian transposition for pelvic malignancies treated by external irradiation or brachytherapy.

C. Haie-meder, P. Morice, P. Duvillard, 1998, Human reproduction.

Results After Conservative Surgery of Stage II/III Serous Borderline Ovarian Tumors

C. Genestie, A. Leary, P. Morice, 2020, Annals of Surgical Oncology.

Long term follow-up of a large series of stage-II/III atypical proliferative serous ovarian tumors.

C. Genestie, A. Leary, P. Morice, 2020, Gynecologic oncology.

How to follow up advanced-stage borderline tumours? Mode of diagnosis of recurrence in a large series stage II-III serous borderline tumours of the ovary.

P. Morice, C. Uzan, S. Gouy, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic factors for patients with advanced stage serous borderline tumours of the ovary.

C. Haie-meder, D. Atallah, P. Morice, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Interest of pelvic and paraaortic lymphadenectomy in patients with stage IB and II cervical carcinoma.

C. Haie-meder, P. Morice, P. Duvillard, 1999, Gynecologic oncology.

Gynecologic Cancer InterGroup (GCIG) Consensus Review for High-Grade Undifferentiated Sarcomas of the Uterus

D. Provencher, I. Ray-Coquard, P. Harter, 2014, International Journal of Gynecologic Cancer.

Adjuvant platinum-based chemotherapy for borderline serous ovarian tumors with invasive implants.

A. Leary, P. Morice, C. Uzan, 2014, Gynecologic oncology.

Fertility results and outcomes after pure laparoscopic management of advanced-stage serous borderline tumors of the ovary.

P. Morice, C. Uzan, S. Gouy, 2010, Fertility and sterility.

Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues.

A. Leary, N. Colombo, P. Morice, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Results of conservative treatment in epithelial ovarian carcinoma

C. Haie-meder, R. de Crevoisier, P. Morice, 2001, Cancer.

Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors.

C. Haie-meder, C. Genestie, S. Culine, 2016, Gynecologic oncology.

Preliminary results of a phase II study to evaluate gefitinib (ZD1839) combined with paclitaxel (P) and carboplatin (C) as second-line therapy in patients (pts) with ovarian carcinoma (OC)

T. Petit, F. Ringeisen, P. Fumoleau, 2004 .

Prognostic value of lymph node involvement in ovarian serous borderline tumors.

P. Morice, C. Uzan, S. Gouy, 2011, American journal of obstetrics and gynecology.

[Is radical surgery (or parametrectomy) needed in all surgical procedure for early stage cervical cancer?].

C. Haie-meder, P. Morice, C. Uzan, 2009, Gynecologie, obstetrique & fertilite.

Neoadjuvant chemotherapy for advanced stage cervical cancer in a pregnant patient: report of one case with rapid tumor progression.

C. Haie-meder, P. Morice, C. Bensaid, 2008, European journal of obstetrics, gynecology, and reproductive biology.

Fertility determinants after conservative surgery for mucinous borderline tumours of the ovary (excluding peritoneal pseudomyxoma).

C. Haie-meder, P. Morice, C. Uzan, 2011, Human reproduction.

Management of epithelial cancer of the ovary, fallopian tube, primary peritoneum. Long text of the joint French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY, endorsed by INCa. (Part 2: systemic, intraperitoneal treatment, elderly patients, fertility preservation, foll

F. Guyon, I. Ray-Coquard, A. Leary, 2019, Journal of gynecology obstetrics and human reproduction.

Results from a Monocentric Long-Term Analysis of 23 Patients with Ovarian Sertoli-Leydig Cell Tumors.

Cyrus Chargari, C. Genestie, A. Leary, 2018, The oncologist.

A New E6/P63 Pathway, Together with a Strong E7/E2F Mitotic Pathway, Modulates the Transcriptome in Cervical Cancer Cells

M. Mori, C. Desaintes, P. Pautier, 2007, Journal of Virology.

A New E 6 / P 63 Pathway , Together with a Strong E 7 / E 2 F Mitotic Pathway , Modulates the Transcriptome in Cervical Cancer Cells

M. Mori, C. Desaintes, P. Pautier, 2007 .

A large retrospective multicenter study of vaginal melanomas: implications for new management

F. Reyal, J. Rodier, T. Filleron, 2013, Melanoma research.

Are serum inhibin concentrations new markers of placental tumours in the course of chemotherapy?

J. Bidart, P. Morice, S. Brailly‐Tabard, 2001, Human reproduction.

Growing Teratoma Syndrome After Ovarian Germ Cell Tumors

C. Patte, P. Duvillard, P. Pautier, 2006, Obstetrics and gynecology.

Serum levels of dimeric activin A are not a marker of placental tumors in the course of chemotherapy

F. Petraglia, J. Bidart, A. Genazzani, 1998, Journal of endocrinological investigation.

Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia.

C. Balleyguier, A. Leary, J. Droz, 2014, European journal of cancer.

CASE REPORT a-Fetoprotein Production by a Malignant Mixed Mullerian Tumor of the Ovary

P. Morice, P. Duvillard, P. Pautier, 2000 .

Surgical Outcomes After Debulking Surgery for Intraabdominal Ovarian Growing Teratoma Syndrome: Analysis of 38 Cases

C. Genestie, C. Balleyguier, A. Leary, 2015, Annals of Surgical Oncology.

Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.

M. Ducreux, E. Raymond, J. Armand, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients

C. Haie-meder, N. Magné, Cyrus Chargari, 2016, Oncotarget.

Chapter 13 The PI 3 K / Akt / mTOR Pathway in Ovarian Cancer : Biological Rationale and Therapeutic Opportunities

A. Leary, P. Pautier, C. Lhommé, 2019 .

The PI3K/Akt/mTOR Pathway in Ovarian Cancer: Biological Rationale and Therapeutic Opportunities

A. Leary, P. Pautier, C. Lhommé, 2013 .

P5-01-07: Identification of SORBS2 as a Candidate Marker To Predict Metastatic Relapse in Breast Cancer.

F. André, P. Dessen, V. Lazar, 2011 .

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

Val Gebski, Philipp Harter, Tomasz Huzarski, 2017, The Lancet. Oncology.

[Targeted therapy in locally and metastatic recurrent cervical cancers].

A. Leary, M. Rodrigues, S. Scholl, 2014, Bulletin du cancer.

Management of Rare Uterine Malignant Tumors

I. Ray-Coquard, F. Amant, M. Friedlander, 2019, Management of Endometrial Cancer.

[Value of inhibin as a tumor marker in granulosa cell tumors. Apropos of 6 new cases treated at the Gustave-Roussy Institute].

J. Bidart, J. Droz, P. Duvillard, 1995, Bulletin du Cancer.

Prognostic factors and morbidities after completion surgery in patients undergoing initial chemoradiation therapy for locally advanced cervical cancer.

C. Haie-meder, P. Morice, C. Uzan, 2010, The oncologist.

A Phase I Trial of High-Dose Chemotherapy Combining Topotecan plus Cyclophosphamide with Hematopoietic Stem Cell Transplantation for Ovarian Cancer: The ITOV 01bis Study

P. Viens, J. Gligorov, S. Richard, 2015, Chemotherapy.

Cancer de l’endomètre

S. Gouy, P. Pautier, R. Mazeron, 2011 .

Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial.

I. Vergote, S. Pignata, I. Ray-Coquard, 2020, JAMA oncology.

Networking for ovarian rare tumors: a significant breakthrough improving disease management

N. Chiannilkulchai, C. Genestie, F. Penault-Llorca, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors

P. Morice, P. Kerbrat, P. Duvillard, 2007, International Journal of Gynecologic Cancer.

Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study.

D. Atallah, P. Morice, C. Pomel, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).

T. Petit, F. Ringeisen, P. Fumoleau, 2010, Gynecologic oncology.

Cisplatin‐based chemotherapy regimen (DECAV) for uterine sarcomas

C. Haie-meder, C. Genestie, A. Le Cesne, 2002, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas

C. Haie-meder, C. Genestie, A. Le Cesne, 2002, International Journal of Gynecologic Cancer.

Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).

I. Vergote, I. Ray-Coquard, I. Benjamin, 2021, Gynecologic oncology.

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.

B. Monk, A. Oza, H. Hirte, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.

A. Gadducci, S. Pignata, C. Sessa, 2021, The Lancet. Oncology.

813MO Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO2/ENGOT Ov-21 trial

A. Oza, J. Ledermann, T. Park-Simon, 2020 .

Kidney Diseases Associated With Anti-Vascular Endothelial Growth Factor (VEGF)

J. Soria, B. Escudier, D. Sahali, 2014, Medicine.

[The molecular biology of epithelial ovarian cancer].

C. Balleyguier, A. Leary, P. Morice, 2012, Bulletin du cancer.

A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study).

F. Bertucci, A. Italiano, I. Ray-Coquard, 2019, European journal of cancer.

Localized high grade endometrial stromal sarcoma and localized undifferentiated uterine sarcoma: a retrospective series of the French Sarcoma Group

J. Blay, F. Bertucci, S. Salas, 2019, International Journal of Gynecologic Cancer.

Recent advances in understanding and managing leiomyosarcomas

S. Salas, I. Ray-Coquard, F. Duffaud, 2015, F1000prime reports.

LMS-02: A phase II single-arm multicenter study of doxorubicin in combination with trabectedin as a first-line treatment of advanced uterine leiomyosarcoma (u-LMS) and soft tissue LMS (ST-LMS): First results in patients with u-LMS.

B. Weber, A. Floquet, F. Selle, 2013 .

Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial

T. Park-Simon, J. Rau, C. Jackisch, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).

J. Blay, F. Collin, S. Piperno-Neumann, 2012, The oncologist.

Evaluation of adjuvant vaginal vault brachytherapy in early stage cervical cancer patients.

C. Haie-meder, C. Genestie, A. Leary, 2020, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Small Cell Carcinoma of the Cervix

D. Provencher, J. Ledermann, I. Treilleux, 2014, International Journal of Gynecologic Cancer.

Expected Benefits of Topotecan Combined With Lapatinib in Recurrent Ovarian Cancer According to Biological Profile: A Phase 2 Trial

Thierry Petit, Sophie Krieger, Nicolas Richard, 2012, International Journal of Gynecologic Cancer.

Phase I clinical trial combining imatinib mesylate and IL-2

L. Zitvogel, A. Eggermont, N. Chaput, 2013, Oncoimmunology.

Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study

F. Goldwasser, C. Gervais, A. Leary, 2021, Pharmaceuticals.

Effects of local laser treatment on vulvovaginal atrophy among women with breast cancer: a prospective study with long-term follow-up

B. Pistilli, S. Delaloge, V. Suciu, 2021, Breast Cancer Research and Treatment.

Prognostic impact of vitamin B6 metabolism in lung cancer.

E. Barillot, I. Wistuba, L. Zitvogel, 2012, Cell reports.

[Initial management of gynecologic cancers: reference guides of the Société Française d'Oncologie Gynécologique (SFOG) ].

C. Haie-meder, I. Barillot, C. Genestie, 2008, Gynecologie, obstetrique & fertilite.

Retroperitoneal Drainage After Complete Para‐aortic Lymphadenectomy for Gynecologic Cancer: A Randomized Trial

C. Haie-meder, N. Lassau, P. Morice, 2001, Obstetrics and gynecology.

The off-label use of targeted therapies in sarcomas: the OUTC’S program

J. Blay, F. Bertucci, A. Le Cesne, 2014, BMC Cancer.

Is systemic disease in the coelomic epithelium associated with BRCA1 germline mutations?

P. Morice, S. Delaloge, B. Bressac-de Paillerets, 2004, Journal of the National Cancer Institute.

Prognostic Factors of a Large Retrospective Series of Mucinous Borderline Tumors of the Ovary (Excluding Peritoneal Pseudomyxoma)

C. Haie-meder, P. Morice, C. Uzan, 2010, Annals of Surgical Oncology.

Safety of simple cystectomy in patients with unilateral mucinous borderline tumors.

L. Salomon, P. Morice, P. Duvillard, 2006, Fertility and sterility.

Pilot Study of the Paclitaxel, Oxaliplatin, and Cisplatin Combination in Patients With Advanced/Recurrent Ovarian Cancer

S. Delaloge, J. Misset, E. Cvitkovic, 2000, American journal of clinical oncology.

Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)

C. Genestie, J. Adam, A. Dunant, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Cancer du col et infection à VIH

P. Morice, R. Crevoisier, P. Pautier, 2003 .

[HIV and uterine cervical cancer].

R. de Crevoisier, P. Morice, P. Pautier, 2003, Bulletin du cancer.

High-Grade Undifferentiated Sarcomas of the Uterus: Diagnosis, Outcomes, and New Treatment Approaches

I. Ray-Coquard, F. Duffaud, C. Philip, 2014, Current Oncology Reports.

Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma.

C. Genestie, G. Le Teuff, A. Leary, 2022, Gynecologic oncology.

Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative

P. Pollock, C. Genestie, H. Mackay, 2018, Modern Pathology.

Implementation of image-guided brachytherapy as part of non-surgical treatment in inoperable endometrial cancer patients.

C. Haie-meder, N. Magné, A. Leary, 2020, Gynecologic oncology.

Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.

F. Bertucci, M. Toulmonde, A. Le Cesne, 2015, The Lancet. Oncology.

Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study.

O. Trédan, F. Gernier, E. Kalbacher, 2019 .

Final results of a FNCLCC French Sarcoma Group multicenter randomized phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS).

F. Collin, S. Piperno-Neumann, N. Penel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.

A. Oza, D. Berton, J. Ledermann, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

B. Monk, A. Oza, M. Birrer, 2019, Annals of Oncology.

Malignant transformation of abdominal wall endometriosis to clear cell carcinoma: case report and review of the literature.

A. Bats, P. Morice, P. Duvillard, 2008, Fertility and sterility.

Impact of primary para-aortic lymphadenectomy on distant failure in locally advanced cervical cancer patients treated in the era of image-guided adaptive brachytherapy

C. Haie-meder, Cyrus Chargari, C. Genestie, 2016, Clinical & Experimental Metastasis.

Histological classification of mucinous ovarian tumors: inter-observer reproducibility, clinical relevance, and role of genetic biomarkers

C. Genestie, J. Scoazec, A. Leary, 2020, Virchows Archiv.

Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO network.

I. Treilleux, I. Ray-Coquard, R. Rimokh, 2014, Gynecologic oncology.

Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours

C. Genestie, A. Dunant, J. Scoazec, 2019, British Journal of Cancer.

Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group.

C. Genestie, F. Guyon, A. Leroux, 2022, Gynecologic oncology.

Replacement of carboplatin by oxaliplatin may be one solution for patients treated for ovarian carcinoma who are hypersensitive to carboplatin.

M. Gutiérrez, P. Pautier, C. Lhommé, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database.

R. Rouzier, P. Colombo, I. Ray-Coquard, 2021, Gynecologic oncology.

A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery

F. Bertucci, M. Toulmonde, A. Le Cesne, 2021, ESMO open.

LBA59 LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma - A French Sarcoma Group study

F. Bertucci, A. Italiano, C. Balleyguier, 2021, Annals of Oncology.

Preservation of pregnancy in a patient with a stage IIIB ovarian epithelial carcinoma diagnosed at 22 weeks of gestation and treated with initial chemotherapy: case report and literature review.

P. Morice, M. Tournaire, P. Pautier, 2004, Gynecologic oncology.

[Gynecological cancers and pregnancy: the point of view of the oncology gynecologist].

C. Haie-meder, P. Morice, C. Pomel, 2002, Bulletin du cancer.

Chemoradiation therapy in pregnant patients treated for advanced-stage cervical carcinoma during the first trimester of pregnancy: report of two cases

C. Haie-meder, P. Morice, P. Duvillard, 2006, International Journal of Gynecologic Cancer.

Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE).

C. Schade-Brittinger, F. Marmé, I. Vergote, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer

C. Genestie, A. Dunant, A. Leary, 2020, Cancer Immunology, Immunotherapy.

Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy.

F. André, P. Dessen, V. Lazar, 2013, Cancer research.

Metabolic features of cancer cells impact immunosurveillance

C. Genestie, G. Kroemer, J. Adam, 2021, Journal for ImmunoTherapy of Cancer.

Immunotherapy-induced Addison's disease: A rare, persistent and potentially lethal side-effect.

M. Haissaguerre, M. Schlumberger, P. Pautier, 2018, European journal of cancer.

Peripheral blood stem cell CD34+ autologous transplant in relapsed follicular lymphoma.

J. Cayuela, C. Gisselbrecht, P. Brice, 1997, Hematology and cell therapy.

Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients

L. Zitvogel, A. Eggermont, N. Chaput, 2013, Oncoimmunology.

Prevention of Menstruation with Leuprorelin (GnRH Agonist) in Women Undergoing Myelosuppressive Chemotherapy or Radiochemotherapy for Hematological Malignancies: a Pilot Study

J. Bourhis, P. Dietrich, J. Pico, 2001, Leukemia & lymphoma.

Lymphoplasmocytic malignant lymphoma presenting with spinal epidural involvement: Four reports of this uncommon lesion

N. Mounier, E. de Kerviler, P. Pautier, 1995, American journal of hematology.

How can laparoscopic management assist radiation treatment in cervix carcinoma?

C. Haie-meder, P. Morice, P. Duvillard, 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Fertility results after conservative treatment of advanced stage serous borderline tumour of the ovary

D. Atallah, P. Morice, P. Duvillard, 2002, BJOG : an international journal of obstetrics and gynaecology.

Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study.

T. Petit, F. Mayer, F. Joly, 2009, Gynecologic oncology.

Interaction between the Number of Chemotherapy Cycles and Brachytherapy Dose/Volume Parameters in Locally Advanced Cervical Cancer Patients

C. Haie-meder, I. Dumas, A. Schernberg, 2020, Journal of clinical medicine.

“Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors”

I. Ray-Coquard, F. Gernier, E. Kalbacher, 2021, BMC Cancer.

Impact of adjuvant treatment modalities on the management of patients with stages I-II endometrial stromal sarcoma.

C. Haie-meder, V. Lazar, C. Balleyguier, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of surgical staging in patients with macroscopic "stage I" ovarian borderline tumours: analysis of a continuous series of 101 cases.

P. Morice, P. Duvillard, P. Pautier, 2004, European journal of cancer.

Mutations in JAK2V617F homologous domain of JAK genes are uncommon in solid tumors

W. Vainchenker, J. Soria, J. Bidart, 2007, International journal of cancer.

Adult granulosa-cell tumor of the ovary: a retrospective study of 45 cases.

S. Culine, J. Bidart, J. Droz, 1997, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Low-dose-rate definitive brachytherapy for high-grade vaginal intraepithelial neoplasia.

C. Haie-meder, I. Dumas, P. Morice, 2011, The oncologist.

Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor.

C. Haie-meder, S. Culine, P. Morice, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical outcome after laparoscopic pure management of borderline ovarian tumors: results of a series of 34 patients.

D. Atallah, P. Morice, P. Duvillard, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors.

P. Morice, P. Duvillard, P. Pautier, 2001, Fertility and sterility.

Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: an analysis of a series of 42 lymphadenectomies.

C. Haie-meder, D. Atallah, P. Morice, 2002, Journal of the American College of Surgeons.

[Borderline ovarian tumours: CNGOFS Guidelines for clinical practice - Hormonal contraception and MHT/HRT after borderline ovarian tumour].

I. Ray-Coquard, C. Rousset-Jablonski, N. Chopin, 2020 .

Endometrioid Borderline Ovarian Tumor: Clinical Characteristics, Prognosis, and Managements

C. Genestie, A. Leary, P. Morice, 2022, Annals of Surgical Oncology.

CT findings in two cases of port-site metastasis after laparoscopy for ovarian cancer.

D. Vanel, P. Morice, P. Pautier, 2002, European Journal of Gynaecological Oncology.

Port-site metastasis after laparoscopic surgery for gynecologic cancer. A report of six cases.

P. Morice, P. Duvillard, P. Pautier, 2000, Journal of reproductive medicine.

[Part I drafted from the short text of the French Guidelines entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa. (Diagnosis management, surgery, perioperative care, and pathological analysis)].

F. Guyon, I. Ray-Coquard, A. Leary, 2019, Gynecologie, obstetrique, fertilite & senologie.

Clear Cell Borderline Ovarian Tumor: Clinical Characteristics, Prognosis, and Management

C. Genestie, A. Leary, P. Morice, 2021, Annals of Surgical Oncology.

Brenner Borderline Ovarian Tumor: A Case Series and Literature Review

C. Genestie, A. Leary, P. Morice, 2021, Annals of Surgical Oncology.

Results after conservative treatment of serous borderline tumours of the ovary with stromal microinvasion but without micropapillary pattern

P. Morice, C. Uzan, S. Gouy, 2009, BJOG : an international journal of obstetrics and gynaecology.

Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Short text of the French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa.

F. Guyon, I. Ray-Coquard, A. Leary, 2019, European journal of obstetrics, gynecology, and reproductive biology.

Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer.

D. Atallah, P. Morice, C. Pomel, 2003, Journal of the American College of Surgeons.

Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry.

C. Genestie, A. Dunant, E. Lanoy, 2020, Gynecologic oncology.

Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT).

C. Genestie, D. Berton, I. Ray-Coquard, 2020, Gynecologic oncology.

Staging surgery in early-stage ovarian mucinous tumors according to expansile and infiltrative types

C. Genestie, A. Leary, P. Morice, 2017, Gynecologic oncology reports.

Primary Psammocarcinoma of the Ovary or Peritoneum

P. Morice, C. Uzan, S. Gouy, 2009, International Journal of Gynecologic Cancer.

Glassy cell carcinoma of the uterine cervix: 20-year experience from a comprehensive cancer center.

C. Haie-meder, C. Genestie, A. Bertaut, 2021, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].

C. Genestie, R. Rouzier, F. Guyon, 2018, Bulletin du cancer.

Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer

A. Oza, A. Gadducci, N. Colombo, 2016, International Journal of Gynecologic Cancer.

False negative rate at 18F-FDG PET/CT in para-aortic lymphnode involvement in patients with locally advanced cervical cancer: impact of PET technology

C. Genestie, A. Leary, P. Morice, 2021, BMC cancer.

[Survival and prognostic factors after completion surgery in patients undergoing initial chemoradiation therapy for locally advanced cervical cancer].

C. Haie-meder, P. Morice, C. Uzan, 2011, Gynecologie, obstetrique & fertilite.

[Para-aortic lymphadenectomy in advanced-stage cervical cancer: standard procedure in 2010?].

C. Haie-meder, P. Morice, C. Uzan, 2010, Gynecologie, obstetrique & fertilite.

Optimizing Local Control in High-Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment.

C. Haie-meder, I. Dumas, Cyrus Chargari, 2017, The oncologist.

[Surgery for uterine sarcoma: review of the literature and recommendations for the standard surgical procedure].

C. Haie-meder, D. Atallah, P. Morice, 2003, Gynecologie, obstetrique & fertilite.

Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone

C. Haie-meder, P. Morice, P. Kerbrat, 2004, International Journal of Gynecologic Cancer.

Cervical Cancer and Fertility-Sparing Treatment

C. Genestie, A. Leary, P. Morice, 2021, Journal of clinical medicine.

Neoadjuvant chemotherapy in fertility-sparing management of FIGO 2018 stage IB2 cervical cancer

C. Genestie, P. Morice, S. Gouy, 2022, International Journal of Gynecological Cancer.

Comprehensive analysis of patient outcome after local recurrence of locally advanced cervical cancer treated with concomitant chemoradiation and image-guided adaptive brachytherapy.

C. Haie-meder, C. Genestie, A. Leary, 2020, Gynecologic oncology.

Therapy Insight: fertility in women after cancer treatment

C. Haie-meder, N. Frydman, R. Fanchin, 2007, Nature Clinical Practice Endocrinology &Metabolism.

Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control study.

C. Balleyguier, C. Robert, B. Besse, 2021, European journal of cancer.

GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer

D. Berton, D. Spaeth, E. Kalbacher, 2020, AntiCancer Research.

Feasibility trial of a combination of vinorelbine, ifosfamide, fluorouracil and folinic acid (VIF regimen) in advanced urothelial cancer.

C. Théodore, J. Droz, J. Kattan, 1993, European journal of cancer.

A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.

M. Campone, A. Stenzl, N. de Bont, 2013, The oncologist.

Adjuvant chemotherapy in stage I ovarian germ cell tumors: should indications and treatment modalities be different in young girls and adults?

A. Leary, P. Morice, C. Uzan, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.

I. Treilleux, E. Kalbacher, A. Floquet, 2020, Gynecologic oncology.

Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer.

C. Genestie, S. Broutin, C. Balleyguier, 2021 .

Multimodal Management of Locally Advanced Neuroendocrine Cervical Carcinoma: A Single Institution Experience

C. Haie-meder, Cyrus Chargari, C. Genestie, 2018, International Journal of Gynecologic Cancer.

Intervention combining nurse navigators (NNs) and a mobile application versus standard of care (SOC) in cancer patients (pts) treated with oral anticancer agents (OAA): Results of CapRI, a single-center, randomized phase III trial.

A. Fourcade, D. Planchard, O. Mir, 2020 .

2755 First real life data on Olaparib in BRCA1/2 mutated Platinum-Sensitive Relapsed (PSR) Epithelial Ovarian Cancer (EOC) in France: Analysis of 52 patients (pts) enrolled in the French Temporary Authorization for Use (ATU)

I. Ray-Coquard, A. Floquet, P. Follana, 2015 .

Isolated leptomeningeal metastasis from ovarian carcinoma: an unusual event.

K. Fizazi, P. Pautier, C. Lhommé, 1998, European journal of cancer.

Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study.

C. Genestie, D. Berton, F. Guyon, 2023, Gynecologic oncology.

Potential clinical activity of pembrolizumab monotherapy in ovarian sex cords, rare epithelial carcinoma, and other rare ovarian tumor histotypes: The French AcSé pembrolizumab study from Unicancer.

F. Bertucci, S. Chevret, I. Ray-Coquard, 2022, Journal of Clinical Oncology.

[French recommendations for endometrial cancer 2010: clinical use and questions still debated].

C. Haie-meder, P. Morice, C. Uzan, 2012, Bulletin du cancer.

Impact of Trabectedin Interruption and Subsequent Rechallenge on Progression in Patients With Advanced Soft Tissue Sarcoma: Long-term Follow-up of the T-DIS trial

J. Blay, F. Bertucci, O. Mir, 2018, American journal of clinical oncology.

H. Dombret, P. Fenaux, S. Thépot, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

F. Pasquier, C. Guillouf, F. Rosselli, 2020 .

Prognostic factors and outcome of undifferentiated endometrial sarcoma treated by multimodal therapy

C. Haie-meder, P. Morice, G. Malouf, 2013, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

Phase I study of ixabepilone given every other week in combination with irinotecan in patients with advanced malignancies.

E. Raymond, J. Armand, S. Faivre, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial.

I. Ray-Coquard, N. Colombo, G. Scambia, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Combined Tumor-Based BRCA1/2 and TP53 Mutation Testing in Ovarian Cancer

C. Genestie, A. Leary, L. Lacroix, 2023, International journal of molecular sciences.

ENGOT-OV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.

R. Wenham, S. Lheureux, I. Vergote, 2019, Journal of Clinical Oncology.

Should Pelvic and Para-aortic Lymphadenectomy Be Different Depending on Histological Subtype in Epithelial Ovarian Cancer?

P. Morice, C. Uzan, S. Gouy, 2007, Annals of Surgical Oncology.

Alpha-fetoprotein production by a malignant mixed Müllerian tumor of the ovary.

P. Morice, P. Duvillard, P. Pautier, 2000, Gynecologic oncology.

A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin in localized uterine sarcomas: Results from 81 randomized patients.

C. Haie-meder, B. Weber, I. Ray-Coquard, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond SMARCA4 Mutations: A Comprehensive Genomic Analysis

M. Rubin, O. Elemento, C. Genestie, 2020, Cells.

Results of Fertility-Sparing Surgery for Expansile and Infiltrative Mucinous Ovarian Cancers.

C. Genestie, A. Leary, P. Morice, 2018, The oncologist.

Characteristics and Prognosis of Stage I Ovarian Mucinous Tumors According to Expansile or Infiltrative Type

C. Genestie, A. Leary, P. Morice, 2018, International Journal of Gynecologic Cancer.

Is uterine preservation combined with bilateral salpingo-oophorectomy to promote subsequent fertility safe in infiltrative mucinous ovarian cancer?

C. Genestie, A. Leary, P. Morice, 2017, Gynecologic Oncology Reports.

Post radiation hysterectomy in locally advanced cervical cancer: Outcomes and dosimetric impact.

C. Haie-meder, I. Dumas, C. Genestie, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Results of conservative treatment of epithelial ovarian tumor.

P. Morice, C. Uzan, S. Gouy, 2009, Gynecologic oncology.

Efficacy of chemotherapy according to BRCA status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse

P. Colombo, I. Ray-Coquard, A. Floquet, 2023, International Journal of Gynecological Cancer.

[Postoperative morbidity after completion surgery following homogeneous chemoradiation therapy in locally advanced cervical cancer].

C. Haie-meder, P. Morice, C. Uzan, 2010, Journal de gynecologie, obstetrique et biologie de la reproduction.

Laparoscopic prophylactic oophorectomy in women with inherited risk of ovarian cancer.

P. Morice, P. Duvillard, A. Spatz, 1999, European Journal of Gynaecological Oncology.

LBA30 Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)

A. Floquet, D. Cibula, F. Heitz, 2022, Annals of Oncology.

Krukenberg tumor: a clinico-pathological study of 15 cases.

A. Fabre, J. Sabourin, P. Morice, 2000, Annales de Pathologie.

[Fertility preservation in cervical cancer, analysis of 30 years of practice and immersion in future developments.]

C. Genestie, C. Balleyguier, A. Leary, 2021, Gynecologie, obstetrique, fertilite & senologie.

Coexistent Uterine Choriocarcinoma and Carcinosarcoma With Lung Metastases

C. Haie-meder, P. Morice, P. Duvillard, 2010 .

[Clinical practice guidelines: 2006 update of recommendations for the radiotherapeutic management of patients with soft tissue sarcoma (sarcoma of the extremity, uterine sarcoma and retroperitoneal sarcoma].

B. Bui, S. Bonvalot, J. Coindre, 2006, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

EP967 Natural history of patients with BRCA-mutated high grade epithelial ovarian cancer (HGEOC) before the era of PARP inhibitors maintenance in 1st line treatment

R. Rouzier, T. Petit, I. Ray-Coquard, 2019, International Journal of Gynecological Cancer.

V. Gebski, A. Oza, J. Ledermann, 2017, The Lancet. Oncology.

Combined topotecan and lapatinib in patients with early recurrent ovarian or peritoneal cancer after first line of platinum-based chemotherapy: A French FEDEGYN-FNCLCC phase II trial.

B. Weber, F. Joly, M. Henry-Amar, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.

D. Timmerman, J. Ledermann, R. Glasspool, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO network.

I. Treilleux, I. Ray-Coquard, R. Rimokh, 2014, Gynecologic oncology.

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

I. Vergote, J. Sehouli, F. Joly, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognosis of stage III or IV primary peritoneal serous papillary carcinoma.

P. Morice, C. Pomel, P. Pautier, 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[Diagnosis of uterine sarcomas and rare uterine mesenchymal tumours with malignant potential. Guidelines of the French Sarcoma Group and Rare Gynaecological Tumours].

C. Genestie, F. Guyon, S. Le Guellec, 2023, Bulletin du cancer.

[Current post-surgical treatment strategies in first-line ovarian cancer].

C. Genestie, A. Leary, P. Morice, 2023, Bulletin du cancer.

Rucaparib in the landscape of PARP inhibition in ovarian cancer

A. Leary, P. Pautier, F. Pommeret, 2019, Expert review of anticancer therapy.

Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

I. Ray-Coquard, N. Colombo, J. Prat, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[Uterin adenosarcoma: French Guidelines of the French Sarcoma Group and the Rare Gynecologic Tumor Group].

J. Blay, C. Genestie, F. Guyon, 2023, Bulletin du cancer.

[Uterin sarcoma, high-grade stroma, indifferenciated, referential].

C. Genestie, F. Guyon, I. Ray-Coquard, 2023, Bulletin du cancer.